OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
IDH Inhibitors in AML—Promise and Pitfalls	38
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	38
MRD Assessment in Multiple Myeloma: Progress and Challenges	34
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments	31
Enteropathy-Associated T cell Lymphoma	20
Treatment-Free Remission: the New Goal in CML Therapy	19
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	18
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	17
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	16
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms	15
Molecular Pathogenesis of Myeloproliferative Neoplasms	15
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding	14
Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges	14
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	14
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	12
Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches	12
Future Directions in Chronic Phase CML Treatment	12
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options	11
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms	11
Antibody-Based Treatment Approaches in Multiple Myeloma	11
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	10
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia	9
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)	9
Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit	9
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	9

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?	9
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job	8
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management	8
The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond	8
BTK Inhibitors in Chronic Lymphocytic Leukemia	8
MRD in ALL: Optimization and Innovations	8
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?	8
Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy	7
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis	7
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	7
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses	7
Management of Chronic Myeloid Leukemia in Children and Young Adults	7
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra	7
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities	7
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma	6
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic	6
The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition	6
Myeloproliferative Neoplasms with Monocytosis	6
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms	6
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies	6
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	6
Targeting BCMA in Multiple Myeloma	6
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	6
Precision Medicine in Myeloid Malignancies: Hype or Hope?	5
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	5
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings	5
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	5
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma	5
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents	5
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine	5
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma	5
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities	5
Bispecific Antibodies for the Treatment of Multiple Myeloma	4
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	4
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions	4
Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse	4
Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia	4
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	4
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions	4
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies	4
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center	4
Progress in the Management of Smoldering Multiple Myeloma	3
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	3
EBV Reactivation and Lymphomagenesis: More Questions than Answers	3
Targeted Therapies for Follicular Lymphoma	3
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries	3
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	3
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	3
Managing Survivorship after Hematopoietic Cell Transplantation	3
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera	3

Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia	3
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery	3
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	3
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma	3
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift	3
Avapritinib in the Treatment of Systemic Mastocytosis: an Update	3